JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Twist Bioscience Corp

Slēgts

SektorsVeselības aprūpe

34.13 7.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32

Max

34.17

Galvenie mērījumi

By Trading Economics

Ienākumi

60M

20M

Pārdošana

3.3M

96M

Peļņas marža

21.227

Darbinieki

923

EBITDA

22M

-24M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+22.34% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 14. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

166M

2B

Iepriekšējā atvēršanas cena

26.74

Iepriekšējā slēgšanas cena

34.13

Ziņu noskaņojums

By Acuity

50%

50%

163 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Twist Bioscience Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. okt. 20:49 UTC

Peļņas

Correction to Thermo Fisher Article on Oct. 22

2025. g. 23. okt. 23:51 UTC

Tirgus saruna

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025. g. 23. okt. 23:37 UTC

Tirgus saruna

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025. g. 23. okt. 22:58 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 23. okt. 22:57 UTC

Tirgus saruna

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -2-

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025. g. 23. okt. 22:17 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025. g. 23. okt. 21:41 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025. g. 23. okt. 21:05 UTC

Peļņas

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 23. okt. 20:35 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025. g. 23. okt. 20:28 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025. g. 23. okt. 20:15 UTC

Tirgus saruna
Peļņas

Global Commodities Roundup: Market Talk

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Adj EPS $1.71

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Sales $5.52B

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q EPS $1.67

2025. g. 23. okt. 20:09 UTC

Peļņas

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025. g. 23. okt. 20:07 UTC

Peļņas

Blackstone Looks to IPOs for Investment Exits -- Update

2025. g. 23. okt. 20:05 UTC

Peļņas

Intel 3Q Gross Margin 38.2% >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel: 4Q Guidance Excludes Altera >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Sees 4Q Adj EPS 8c >INTC

Salīdzinājums

Cenas izmaiņa

Twist Bioscience Corp Prognoze

Cenas mērķis

By TipRanks

22.34% augšup

Prognoze 12 mēnešiem

Vidējais 38 USD  22.34%

Augstākais 50 USD

Zemākais 25 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Twist Bioscience Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

6

Pirkt

1

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

31.56 / 38.6884Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

163 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat